论文部分内容阅读
肿瘤逃避机体免疫排斥的机制之一,是肿瘤细胞存在的肿瘤相关抗原的免疫原性较弱,不足以引起宿主有效的抗肿瘤免疫反应。NDV可以改变或影响瘤细胞的免疫原性,诱发和促进机体对肿瘤的排斥反应。本文探讨了新城疫病毒(new castle disease virus,NDV)对小鼠H_(22)腹水瘤的治疗作用。对照组接种H_(22)瘤细胞后第8d死亡1只,至第16d10只小鼠全部死亡,存活率为0％,平均存活14.1d。实验组注射瘤细胞后第12d死亡2只,至23d死亡9只,1只无瘤存活,存活率为10％。死亡鼠平均存活天数为18d,比对照组延长3.9d,两组相差显著(P<0.05)。实验结果表明NDV对小鼠H_(22)腹水瘤有治疗作用,能抑制小鼠H_(22)腹水瘤的生长,可延长小鼠生存时间。NDV可作治疗肿瘤的一种新生物制剂。
One of the mechanisms by which tumors evade immune rejection is that tumor-associated antigens present in tumor cells have weak immunogenicity and are not sufficient to cause effective anti-tumor immune responses in the host. NDV can alter or affect the immunogenicity of tumor cells, induce and promote the body’s rejection of tumors. This article discusses the therapeutic effect of newcastle disease virus (NDV) on H_22 ascites tumor in mice. After the control group was inoculated with H_(22) tumor cells, it died on the 8th day and all mice died on the 16th day. The survival rate was 0% and the average survival time was 14.1 days. In the experimental group, 2 tumor cells were injected on the 12th day after the injection of tumor cells, and 9 cells died on the 23rd day. One tumor-free cell survived and the survival rate was 10%. The average number of survival days of dead mice was 18 days, which was 3.9 days longer than that of the control group. The difference between the two groups was significant (P<0.05). The experimental results show that NDV has a therapeutic effect on mouse H_22 ascites tumor and can inhibit the growth of H_22 ascites tumor in mice and prolong the survival time of mice. NDV can be used as a new biological agent for the treatment of tumors.